Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy

Next Previous
Trial Profile

Phase 1, Multicenter, Open-Label, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 Added to Background Pulmonary Arterial Hypertension (PAH) Therapy

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HS 135 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors 35Pharma

Most Recent Events

  • 30 May 2025 Status changed from active, no longer recruiting to discontinued.
  • 12 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 04 Dec 2024 Planned End Date changed from 1 Apr 2027 to 1 Jul 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top